By Williams Anuku, Abuja
Pharmaceutical giant Pfizer Monday, announced that its coronavirus vaccine trial was effective in preventing COVID-19 infections in 90 per cent of previously uninfected people.
It also stated that early testing did not produce any serious safety concerns or side effects.
With the latest development, it would potentially be a huge breakthrough in the fight against the coronavirus pandemic.
Pfizer said it will go to the FDA by the end of the month for an emergency use authorization.
Pfizer, who developed the vaccine in conjunction with German pharmaceutical company, BioNTech, says that they have enrolled “43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of Nov. 8, 2020.”
“The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued,” Axios reports.
The company “released only sparse details” from the trial, and scientists “have cautioned against hyping early results before long-term safety and efficacy data has been collected.”
